Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety profile New antibody-drug conjugate (ADC) candidate, ZW327, exhibits anti-tumor activity and a favorable pharmacokinetics profile in Ly6E-bearing cancers VANCOUVER, British Columbia, March 25, 2025 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse […]
Zymeworks will present preclinical data on T cell engager and antibody-drug conjugate platforms in six posters at the AACR Annual Meeting. Highlights include: ZW209, a novel trispecific T cell engager targeting DLL3 with an encouraging safety profile; ZW327, a new antibody-drug conjugate (ADC) candidate targeting Ly6E with anti-tumor activity; ZW171, a differentiated T cell-engaging bispecific antibody with antitumor activity in mesothelin-expressing cancers; and biparatopic antibody-drug conjugates against protein tyrosine kinase 7. Additionally, Zymeworks scientists co-authored two presentations on ADC design and characterization.
